



**Imbed**  
BIOSCIENCES

**BIOLAB**  
HOLDINGS

# **Microlyte<sup>®</sup> SAM<sup>™</sup>** **Antimicrobial Technology**

**There is No Substitute for SAM<sup>™</sup>**




**The First and ONLY Fully Synthetic,  
Antimicrobial, Biocompatible Matrix.**

# Protect Wounds with **SAM™**

**SAM™ Antimicrobial Technology** is advancing the science of skin regeneration as the **ONE** and **ONLY** matrix on the market that is fully synthetic, antimicrobial, and biocompatible.

# Microlyte®

**SAM™** Antimicrobial Technology




**Indicated for the treatment of chronic, acute, burn and surgical wounds**



**SAM™ - the revolutionary platform technology behind Microlyte®** – designed to support wound healing by immediately conforming to the micro-crevices of the wound bed, and allowing for cellular growth while sustaining a consistent reduction in microbial burden.


## Delivering Integrated Wound Solutions

- ✓ Fully synthetic ultra-thin, porous matrix made of bioresorbable polymers and designed to mimic human ECM<sup>1-3</sup>
- ✓ Conforms to the micro-textures of the wound bed<sup>1,2</sup> with full transparency



- ✓ Rapidly transforms into a biocompatible, cytophilic, nonpyrogenic soft matrix upon contact with wound fluid, to create a moist wound-healing environment<sup>1-3</sup> - called the SAM™ Scaffolding Effect

- ✓ Antimicrobial, containing ionic and metallic silver at a low, non-toxic level, providing 99.99% reduction in microbial burden<sup>†4</sup>



- ✓ Microlyte® SAM™ can be used at onset of wound treatment or in surgery, including in conjunction with other wound management technologies and solutions

# Proven Outcomes

## A New Standard-of-Care

In two peer-reviewed, published studies, Microlyte® SAM™ enabled closure of previously stalled chronic wounds and reduced surgical site infections (SSIs), respectively.

**In a study of diabetic patients** undergoing foot or ankle surgery (N=22):<sup>5</sup>



0%

**SSI rate** vs. historical  
13% expected SSI rate in  
this population

100%

**heal rate** of per-protocol  
population in an average of  
21 days\*

**In a study of patients with DFUs and VLU**s that were non-healing  
for an average of 40 weeks (N=32):<sup>6</sup>

91%

of wounds **healed  
completely or improved  
significantly** within 12 weeks

73%

**average wound area  
reduction** within 12 weeks



# How Can Microlyte® SAM™ Help You...

## ...Protect the Patients You Care For.

### Contact a Representative Now

Email: [orders@blssales.net](mailto:orders@blssales.net)

Phone: 602.830.5100

#### REFERENCES:

1. Agarwal A, et al. Surfaces modified with nanometer-thick silver-impregnated polymeric films that kill bacteria but support growth of mammalian cells. *Biomaterials*. 2010;31(4):680-90.
2. Study 15T\_41113\_02, Systemic Toxicity, Local Tissue Response, and Wound Healing Study of MicroLyte Ag, Following Repeated Treatment to Full-Thickness Wounds in Rats – 28 Days. Data on file, Imbed Biosciences.
3. MTT cytotoxicity testing conducted at NAMSA. Data on file, Imbed Biosciences.
4. Study 15-002, Microlyte Shelf Life and Stability. Data on file, Imbed Biosciences.
5. Chatelain R. The efficacy of a novel silver-containing bioresorbable microfilm matrix in at-risk surgical wounds: a clinical case series. *Wounds*. 2021;33(10):245–252.
6. Manning SW, et al. Efficacy of a Bioresorbable Matrix in Healing Complex Chronic Wounds: An Open-Label Prospective Pilot Study. *Wounds*. 2020;32(11):309-318.

\* In 2 patients, time to healing was delayed secondary to weight-bearing dehiscence.

† As demonstrated *in vitro*

These materials contain information about products that may or may not be available in any particular country or may be available under different trademarks in different countries. The products may be approved or cleared by governmental regulatory organizations for sale or use with different indications or restrictions in different countries. Products may not be approved for use in all countries. Nothing contained on these materials should be construed as a promotion or solicitation for any product or for the use of any product in a particular way which is not authorized under the laws and regulations of the country where the reader is located. Specific questions physicians may have about the availability and use of the products described on these materials should be directed to their particular local sales representative. Specific questions patients may have about the use of the products described in these materials or the appropriateness for their own conditions should be directed to their own physician.

© 2025 Imbed Biosciences, Inc.  
Distribution: BioLab Holdings  
2260 W. Broadway Rd. Suite 102  
Mesa, AZ 85202  
[info@biolabholdings.net](mailto:info@biolabholdings.net)  
Phone: 602.830.5100



**Imbed**  
BIOSCIENCES

**BIOLAB**  
HOLDINGS